WeissLaw LLP: The Proposed Acquisition of SciClone Pharmaceuticals Inc. May Not Be In the Best Interest of SCLN Shareholders

Jun 12, 2017 - (Newswire)

- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of SciClone Pharmaceuticals Inc. ("SCLN" or the "Company") (NASDAQ: SCLN) in connection with the proposed acquisition of the Company by a consortium led by GL Capital Management GP Limited (the "Consortium") for approximately $605 mill

Original Source: https://www.newswire.com/news/weisslaw-llp-the-proposed-acquisition-of-sciclone-pharmaceuticals-inc-may-not

What Next?

Related Articles

Leave a Reply

Submit Comment